Earnings Releases·Nov 12, 2026, 4:05 PM ET

Journey Medical Corporation — Third Quarter 2026 Earnings Summary

Total revenue increased 8% year-over-year to $19.0 million, driven by an 84% surge in Emrosi® sales to $9.0 million, while gross margin expanded to 69% from 67%.
GAAP net loss narrowed to $1.3 million ($0.05 per share) from $2.3 million in the prior-year quarter, with the company reporting positive EBITDA for both the three and nine-month periods.
SG&A expenses rose $0.5 million to $12.6 million, primarily due to a $1.7 million one-time vendor dispute settlement, partially offset by reduced launch spending.
Management highlighted strong Emrosi® prescription trends (approx. 40,000 TRx) and expressed confidence in future market penetration via formulary additions and an expanded sales force.
Balance sheet shifts included cash decreasing to $22.3 million, while accounts receivable and total liabilities increased to $47.4 million and $71.6 million, respectively, driven by a $7.5 million short-term loan.